Evaluation of chimpanzee adenovirus and MVA expressing TRAP and CSP from Plasmodium cynomolgi to prevent malaria relapse in nonhuman primates
Plasmodium vivax is the world's most widely distributed human malaria parasite, with over 2.8 billion people at risk in Asia, the Americas, and Africa. The 80-90% new P. vivax malaria infections are due to relapses which suggest that a vaccine with high efficacy against relapses by prevention o...
Main Authors: | Kim, YC, Dema, B, Rodriguez-Garcia, R, López-Camacho, C, Leoratti, FMS, Lall, A, Remarque, EJ, Kocken, CHM, Reyes-Sandoval, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
MDPI
2020
|
Similar Items
-
Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from <i>Plasmodium cynomolgi</i> to Prevent Malaria Relapse in Nonhuman Primates
by: Young Chan Kim, et al.
Published: (2020-07-01) -
A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
by: Ewer (nee Russell), K, et al.
Published: (2016) -
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
by: Ewer, K, et al.
Published: (2013) -
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
by: Green, C, et al.
Published: (2015) -
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
by: Green, C, et al.
Published: (2023)